Has Elaine Su, MD received payments from drug or device companies?

Yes. Drug and device makers reported $7,242 in general payments to Elaine Su, MD across 38 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Elaine Su, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Elaine Su, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Elaine Su, MD

Neurology · Los Angeles, CANPI 1073908414

Payments from drug & device makers

$7,242in general payments, 2019–2025

Across 38 payments — averaging $190.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Genentech USA, Inc.$4K
Genentech, Inc.$2K
Biogen$277
Amgen$272
AstraZeneca$243
Novartis$137
plus $88 from 1 others

What the payments were for

Consulting fees$6,27587%
Food & beverage$5748%
Education$3935%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Genentech USA, Inc.	3	$4,345
Genentech, Inc.	1	$1,880
Biogen	3	$277
Amgen	21	$272
AstraZeneca	2	$243
Novartis	7	$137
EMD Serono, Inc.	1	$88

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

OCREVUS$4,165
Enspryng$2,060
TYSABRI$150
SOLIRIS$121

How this compares

$7,242 in reported general payments places this provider in the 65th percentile of 1,996 neurology providers in California.

See all neurology providers in California →

Medicare billing

Part B allowed, 2024

$8,127

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Kesimpta PenOfatumumab	15	$139,925
Avonex Pen (4 Pack)Interferon Beta-1a	11	$88,975
Glatiramer Acetate	15	$43,450
Dalfampridine ErDalfampridine	56	$11,787
Baclofen	76	$1,345
Gabapentin	46	$1,260
Duloxetine Hcl	22	$803
Levetiracetam	12	$364
Nortriptyline Hcl	14	$316

Paid to pharmacies, not to this prescriber.

Other neurology in Los Angeles

Timothy CloughesyLos Angeles$33.1M
Perry ShiehLos Angeles$8.2M
Jeffrey SaverLos Angeles$2.9M
David PiccioniLos Angeles$2.9M
David LiebeskindLos Angeles$2.7M
Michele TagliatiLos Angeles$2.5M
Jennifer HuiLos Angeles$2.4M
Susan PerlmanLos Angeles$2.2M
Jeffrey CummingsLos Angeles$2M
Bryan SpannLos Angeles$1.8M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →